Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23375945 | 0.93 | KDM4E (0.54) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL28050894 | 0.91 | FBP1 (0.44) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL7922511 | 0.85 | SMPD1 (0.45) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL168783 | 0.85 | CA2 (0.48) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL30360640 | 0.85 | CA2 (0.48) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL29101743 | 0.83 | SMPD1 (0.50) | PDE4B | |
| SCHEMBL15869350 | 0.82 | TRPV4 (0.56) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL1964286 | 0.82 | TRPV4 (0.56) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL16959014 | 0.82 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL6197396 | 0.82 | MAPK1 (0.49) | PDE4APDE4BPDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324404-B2 | 3-thia-10-aza-phenanthrene derivatives | NYCOMED GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324404-B2 | 3-thia-10-aza-phenanthrene derivatives | NYCOMED GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324404-B2 | 3-thia-10-aza-phenanthrene derivatives | NYCOMED GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| WO-2012097116-A2 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | CELGENE CORPORATION (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-1797098-B1 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | NYCOMED GMBH (DE) | 2011-05-04 | — | — | EP | disclosed |
| EP-1797098-B1 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | NYCOMED GMBH (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090239895-A1 | Novel 3-thia-10-aza-phenanthrene derivatives | NYCOMED GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20080103168-A1 | Novel 3-Thia-10-Aza-Phenanthrene Derivatives | ATLANA PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1797098-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1791847-A2 | NOVEL 3-THIA-10-AZA-PHENANTHRENE DERIVATIVES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027345-A2 | NOVEL 3-THIA-10-AZA-PHENANTHRENE DERIVATIVES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027345-A2 | NOVEL 3-THIA-10-AZA-PHENANTHRENE DERIVATIVES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027344-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027344-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103168-A1 | Novel 3-Thia-10-Aza-Phenanthrene Derivatives | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
| US-20090239895-A1 | Novel 3-thia-10-aza-phenanthrene derivatives | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.